

1. Title Page

Title

Impact of Antibodies that React with Liver Tissue and Donor-specific anti-HLA
Antibodies in Pediatric Idiopathic Posttransplantation Hepatitis

Author listing

Yoshihiro Hirata MD ¹, Atsushi Yoshizawa MD, PhD ¹, Hiroto Egawa MD, PhD ²,
Daisuke Ueda MD ¹, Shinya Okamoto MD, PhD ¹, Hideaki Okajima MD, PhD
¹, Kimiko Yurugi ³, Rie Hishida ³, Hideyo Hirai MD, PhD ³, Aya
Miyagawa-Hayashino MD, PhD ⁴, Taira Maekawa MD, PhD ³, Hironori Haga MD,
PhD ⁴, and Sinji Uemoto MD, PhD ¹

¹ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto
University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku Kyoto 606-8507,
JAPAN

² Institute of gastroenterology, Tokyo Women's Medical University, 8-1,
Kawatacho, Shinjuku, Tokyo 162-8666, JAPAN

³ Department of Transfusion Medicine and Cell Therapy, Kyoto University

Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku Kyoto 606-8507, JAPAN

⁴ Department of Diagnostic Pathology, Kyoto University Hospital, 54
Kawaharacho, Shogoin, Sakyo-ku Kyoto 606-8507, JAPAN

Correspondence information

Dr. Atsushi Yoshizawa

Department of Surgery, Graduate School of Medicine, Kyoto University

Telephone number: +81-75-751-4323

Fax number: +81-75-751-4323

E-mail: ayoshi14@kuhp.kyoto-u.ac.jp

2. Authorship Page

Y.H. participated in the research design, writing and revision of the article, data analysis, and data collection. A.Y. participated in the research design, data analysis, and revision of the article. H.E. participated in the revision of the article. D.U., S.O. , H.O. , K.Y., R.H., K.K., Y.R., and H.H. participated in the data collection. A.M-H., and H.H. participated in the pathological diagnosis. T.M. participated in the data collection. S.U. participated in the research design, and revision of the article.

Funding

This work was supported in part by the Special Coordination Funds for Promoting Science and Technology of the Japanese Government and by Astellas Pharma Inc. in the Formation of Innovation Center for Fusion of Advanced Technologies Program.

This work was funded in part by the AK Project (between Astellas Pharma Inc. and Kyoto University). However, the study was designed, conducted, analyzed, and reported independently of the funding agencies and pharmaceutical companies.

Disclosure

The authors declare no other potential conflicts of interest relevant to this article.

3. Abbreviations Page

AIH, autoimmune hepatitis; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; APOLT, auxiliary partial orthotopic liver transplantation; ARLT, antibodies that react with liver tissue; ASMA, anti-smooth muscle antibodies; CK, cytokeratin; ELISA, enzyme-linked immunosorbent assay; HLA-DSA, donor-specific anti-human leukocyte antigens antibodies; HCV, hepatitis C virus; HLA, human leukocyte antigens; IPTH, idiopathic posttransplantation hepatitis; LKM, liver kidney microsomal antibodies; LTx, liver transplantation; MFI, mean fluorescence intensity; PFIC, progressive familial intrahepatic cholestasis; R^2 , Pearson's correlation coefficient

4. ABSTRACT

Background: The cause of late graft dysfunction has not been elucidated. Although an antibody-mediated reaction is suspected as a potential mechanism, the target antigens have not been clarified.

Methods: To clarify the etiology of idiopathic posttransplantation hepatitis (IPTH), we simultaneously examined the presence of antibodies that react with liver tissue (ARLT) by means of indirect immunofluorescence staining, as well as the presence of donor-specific anti-human leukocyte antigen antibodies (HLA-DSA). A subanalysis of the IPTH group was also performed. Within the IPTH group, the correlation between ARLT titer and clinical data were analyzed.

Results: In the sera of patients with IPTH (30 patients), ARLT were found at a significantly higher frequency than in patients without IPTH (42 patients; $p < 0.001$). Moreover, the ARLT titer appeared to be correlated with the severity of hepatitis or hepatic injury. In contrast, the frequency of HLA-DSA was significantly lower in patients with IPTH than in patients without IPTH ($p = 0.001$).

Conclusion: Our findings indicate that ARLT, and not HLA-DSA, profoundly influence the etiology of IPTH.

5. Main Body Text

INTRODUCTION

The etiology of late graft dysfunction has been widely investigated, and various mechanisms have been proposed ¹⁻⁵. One of the potential mechanisms of chronic graft injury are humoral immune response. We previously reported that graft liver fibrosis, which is prominent in the centrilobular area and is observed in patients after liver transplantation (LTx), is caused by humoral immunity ⁶.

Idiopathic posttransplantation hepatitis (IPTH) is a type of late-phase graft injury that may lead to graft dysfunction ². One of the pathological features of IPTH is interface hepatitis ⁷. *De novo* interface hepatitis after LTx was first reported in 1998, and most patients showed elevation of anti-nuclear antibodies (ANA) ⁸. Thereafter, there were many reports of *de novo* interface hepatitis after LTx ⁹⁻¹³. Moreover, a correlation between interface hepatitis and autoantibodies was reported ⁷. However, some patients of interface hepatitis showed no elevation of autoantibodies, and the concept of IPTH was proposed to explain this discrepancy ². Because the pathological findings of IPTH mimic those of autoimmune hepatitis (AIH), humoral immunity has been hypothesized to be

associated with IPTH etiology ⁷. Herein, we encountered some patients who had refractory interface hepatitis without autoantibody elevation. We hypothesized that unidentified antibodies are profoundly correlated with interface hepatitis, and investigated these unidentified antibodies.

In this study, indirect immunofluorescence staining in rat liver tissue, which is a classical technique to detect autoantibodies, was performed to detect antibodies that react with liver tissue (ARLT) in the sera of transplanted recipients. Donor-specific anti-human leukocyte antigen antibodies (HLA-DSA) were examined simultaneously.

MATERIALS AND METHODS

This study was approved by the institutional review board of Kyoto University, and a waiver for consent was obtained for patient sera collection. All experimental protocols were approved by the Animal Research Committee of Kyoto University. All animals received humane care according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication 86-23, 1985 revision). Male Wistar rats weighing ~200 g were obtained from Japan SLC, Inc. (Shizuoka, Japan).

Patients

Of the 851 pediatric patients (under 20 years old) who underwent LTx in Kyoto University between June 1991 and December 2012, 48 patients (5.6%) were diagnosed with IPTH, and 30 of 48 patients were followed up in our institution from June 2011 to December 2012 and were enrolled in this study. Liver biopsies were performed during this period, and serum samples were collected at the same time from 24 of 30 patients. The other six patients had already undergone liver biopsy earlier (January 2010 to May 2011). For these six patients, the laboratory data collected at liver biopsy and serum sampling were compared. There was relatively little difference between the two data sets, indicating that the status of the graft liver was roughly the same and that the collected serum could be used in this examination. Sera from all 30 patients were collected and stored at -80°C until further use.

The control patients were selected from among patients who underwent liver biopsies from June–December 2011. The exclusion criteria included patients whose original disease was viral hepatitis infection or an autoimmune disease. The control patients were selected to match the background of the

patients, including age at LTx, follow-up period, and gender. Finally, 42 patients were selected. The control group was divided into three subgroups based on pathological findings (Figure 1). The details are explained in the section on pathological examination. Sera from 42 patients were collected at the same time as the liver biopsy and stored at -80°C until further use.

The characteristics of the patients are shown in Table 1. There were no significant differences in the age at LTx, follow-up period, gender, original disease, and graft type. A significantly greater proportion of patients required steroid administration in the IPTH group than in the control group ($p < 0.001$).

Immunosuppression

The immunosuppression protocol consisted of tacrolimus and low-dose steroids^{14,15}. The target whole blood trough level of tacrolimus was 10–12 ng/mL for the first two weeks, ~10 ng/mL for the following two weeks, and 8–10 ng/mL thereafter. The trough level of tacrolimus was gradually decreased one year post-transplant. The tacrolimus trough level was decreased as much as possible if the transaminase and bilirubin levels were within the normal range for 2 years.

Methylprednisolone-treatment was initiated at the time as graft

reperfusion at a dose of 10 mg/kg, tapered from 1 mg/kg/day to 0.3 mg/kg/day during the first month, and finally withdrawn within the first three months ¹⁶.

The treatment for liver injury with interface hepatitis consisted of pulsed doses of methylprednisolone, 10 mg/kg/day for 3 days, which was gradually tapered. Oral prednisolone (0.1–0.5 mg/kg/day) was continued after steroid pulse therapy. The current status of immunosuppressive drugs is described in Table 1.

Pathological examination

For the biopsy, liver tissue was obtained percutaneously with an 18-gauge needle, and sections were stained with hematoxylin-eosin, azan, and cytokeratin 7. All liver biopsy samples were assessed by the same two pathologists (H. H. and A. M-H).

IPTH is defined as elevated transaminase levels in clinical laboratory data and pathologic interface hepatitis with unknown cause. Patients whose original disease was hepatitis virus infection or autoimmune disease were excluded because these diseases can recur after LTx and cause interface hepatitis. The diagnosis of IPTH does not require an elevation of autoantibodies.

IPTH relapse was defined as elevated liver function test findings and interface hepatitis (as assessed by pathological examination) in patients who had been diagnosed with IPTH previously. The possibility of hepatitis virus infection was excluded. Although the presence of autoantibodies was not included in the criteria, the autoantibodies levels were also examined

Interface hepatitis was diagnosed by the presence of predominantly mononuclear portal inflammatory infiltrates associated with inflammatory spillover into the periportal zones ⁷. The degree of hepatitis activity and fibrosis was evaluated by using the METAVIR scoring system ^{17,18}.

Inflammation was defined as inflammatory cell infiltration of the portal or centrilobular area without interface hepatitis. Inflammation included late-onset acute rejection (LAR), and LAR was defined as acute cellular rejection appearing later than 1 year after transplantation without interface hepatitis ².

Additionally, fibrosis of the portal and centrilobular area was evaluated. The METAVIR scoring system was used to evaluate portal fibrosis ^{18,19}. The modified staging system of nonalcoholic fatty liver disease devised by the pathology committee of the Nonalcoholic Steatohepatitis Clinical Research Network was used to evaluate centrilobular fibrosis ⁷. Severe fibrosis was

defined as the appearance of bridging fibrosis, portal to centrilobular or portal to portal, without inflammation.

C4d immunostaining

C4d immunostaining was performed using a polyclonal anti-human C4d antibody (BI-RC4D, Biomedica, Vienna, Austria) diluted at 1:50. Evaluation of C4d immunostaining was performed as follows: C4d deposition in the vascular endothelium was regarded as positive staining, while C4d deposition on the elastic fibers or stroma without the vascular endothelium was regarded as non-specific or negative staining, respectively. Portal C4d immunolabeling of >50% of the portal tracts was considered to indicate diffuse staining, and <50% represented focal staining^{6,20}.

Detection of antibodies that react with liver tissue (ARLT)

ARLT were detected by indirect immunofluorescence, which was previously utilized to detect ANA^{21,22}. Rat liver tissue was used instead of human liver tissue as an antigen because human liver tissue contains human IgG, and indirect immunofluorescence staining with human liver tissue would detect the

IgGs in human liver tissue as well as those in the patient sera (primary antibody).

Rat liver tissue was harvested after euthanasia, frozen in liquid nitrogen, cut into 5- μ m-thin sections, and mounted onto glass slides. Sections were air-dried and fixed in 90% ethanol and acetone, and blocked with 1% bovine serum albumin. Sections were then incubated with preserved sera from the study participants in a humidified chamber overnight at 4 °C. After gentle washing, sections were incubated with anti-human IgG conjugated with CF488A dye (Biotium, Inc. Hayward, CA USA) for 1 h at room temperature. Images were obtained with a Carl Zeiss AxioVision system, and all of the settings, including the magnification (100 $\times$) and exposure time (50 ms), were the same for each image.

The intensity of the stained cytoplasm within the hepatocytes was measured using ImageJ (National Institutes of Health, Bethesda, MD, USA). The average of the intensities of four randomly selected areas of cytoplasm was calculated for each patient. Immunofluorescence intensity has previously been reported to show a good correlation with the antibody titer in human serum ²³. We considered the calculated intensity to reflect the ARLT titer. The cut-off value was defined as the maximum intensity based on 10 serum samples from healthy

volunteers. A value over the cut-off was defined as “positive” and a value >2-times the cut-off value was defined as “strongly positive.”

IgG subclasses of ARLT were examined in IPTH patients. Frozen rat liver sections were incubated with diluted serum from a patient. The secondary antibodies were anti-human IgG1, IgG2, IgG3, and IgG4 conjugated with fluorescein isothiocyanate (Binding Site, Birmingham, UK). The intensities of IgG1, IgG2, IgG3, and IgG4 staining were then compared.

Detection of donor-specific anti-HLA antibodies (HLA-DSA)

The same serum samples that were used for the immunofluorescence staining analysis were also used for the HLA-DSA detection assay. The sera were analyzed for anti-HLA antibodies using LABScreen mixed beads (One Lambda, Canoga Park, CA, USA) and a Luminex analyzer according to the manufacturer’s protocol. When anti-HLA antibodies were detected, the antibody-responsive HLA was identified using a LABScreen single-antigen assay (One Lambda) in order to determine the donor specificity. A normalized, trimmed value for the mean fluorescence intensity (MFI) $\geq 1,000$ was considered positive^{20,24}. Donor HLA typing of six patients in the IPTH group and four

patients in the control group had not been performed before LTx, and thus, they were excluded from the HLA-DSA study.

Autoantibody measurement

We measured ANA, liver kidney microsomal antibodies (LKM), and anti-smooth muscle antibodies (ASMA) in IPTH patients. ANA and ASMA were measured using fluorescence antibody assay. The cut-off value was 1:40 for ANA and 1:20 for ASMA. LKM was measured using enzyme-linked immunosorbent assay (ELISA). The cut-off value was 17, but values of 17–51 were considered suspicious, while values >51 were considered definitely positive.

Statistical analysis

Clinical groups were compared using Mann-Whitney U test. Kruskal-Wallis test was used to compare continuous variables among multiple groups. The chi-squared test or Fisher's exact test was used to compare categorical variables. A *p* value of <0.05 was considered to represent statistical significance. All statistical analyses were performed using JMP 11.0 (SAS

Institute Inc., Cary, NC, USA).

RESULTS

ARLT and HLA-DSA data

Representative images of immunofluorescence staining are shown in Figure 2. First, the ARLT- or HLA-DSA-positive rate was compared between the IPTH and control groups (Table 2). The ARLT-positive rate was significantly higher in the IPTH group (86.2%) than in the control group (30.9%; $p < 0.001$), whereas the HLA-DSA-positive rate was significantly lower in the IPTH group (12.5%) than in the control group (50.0%; $p = 0.001$). The classification of HLA-DSA is shown in Table 2. Among the HLA-DSA-positive patients, HLA-DSA class II comprised 100% and 94.7% of the IPTH and control groups, respectively. In the IPTH group, DQ and DR loci were each detected in two patients. In the control group, the DQ locus was detected in 14 patients and the DR locus was detected in 15 patients. There were no significant differences between the presence of DR and DQ loci in both groups.

To investigate the relationship between ARLT or HLA-DSA and the pathological findings, the control group was divided into three groups according

to the pathological findings. The inflammation group comprised patients who showed inflammation with or without severe fibrosis ($n = 13$), the fibrosis group comprised patients who showed severe graft liver fibrosis without inflammation ($n = 14$), and the remaining patients who showed no typical pathological findings were included in the normal group ($n = 15$).

The fluorescence intensity of ARLT and HLA-DSA were compared among the four groups in order to investigate these antibodies in detail. The fluorescence intensity of ARLT of each group is shown in Figure 3-1. The fluorescence intensity of the IPTH group (58.5 ± 23.2) was significantly higher than that of the other groups (23.7 ± 12.0 , 37.4 ± 12.0 , and 28.5 ± 6.4 for the inflammation, fibrosis, and normal groups, respectively; $p < 0.001$). Conversely, the MFI of HLA-DSA was significantly lower in the IPTH group ($1,270 \pm 3,662$) than in the other groups ($9,929 \pm 10,899$, $12,204 \pm 11,023$, and $5,509 \pm 8,966$ for the inflammation, fibrosis, and normal groups, respectively; $p < 0.001$).

The comparisons of the clinical data of the four pathological groups are shown in Table 3. AST, ALT, g-GTP, T-Bil, Plt, and IgG levels showed no significant differences among the four groups.

Location of severe fibrosis

Severe fibrosis of the portal or centrilobular area was compared among the groups (Table 4). Severe fibrosis of the portal area was more frequently observed in the IPTH group than in the other groups ($p = 0.002$). Conversely, severe fibrosis of the centrilobular area was more frequently observed in the fibrosis group ($p < 0.001$).

Subanalysis within the IPTH group

To investigate the effect of ARLT in IPTH, the IPTH group was divided into three groups according to the fluorescence intensity of ARLT (four patients were negative, 16 were positive, and 10 were strongly positive).

The clinical data, IgG subclass of ARLT, clinical autoantibodies, and C4d staining of liver biopsy sample were evaluated.

ARLT and clinical data in IPTH patients

We compared the AST, ALT, and γ -GTP levels, the age at LTx and follow-up period, and the time of IPTH onset from LTx among the three groups (Table 5). Increased AST and ALT levels were observed in the strongly positive

group compared with the positive or negative group; this difference was significant with respect to the ALT level ($p = 0.03$). There was no elevation in serum IgG titer in the positive and strongly positive groups compared with the negative group.

IgG subclass of ARLT in IPTH patients

We examined the levels of IgG subclasses in 26 patients with positive immunofluorescence staining (Figure 4). Twenty-four patients showed IgG1 positivity, one patient showed IgG3 positivity, and one patient showed IgG4 positivity.

Correlation between the fluorescence intensity of ARLT and liver damage

Three patients experienced liver injury because of interface hepatitis during this study. Autoantibodies were not detected in these three patients when the interface hepatitis relapsed. The fluorescence intensity of ARLT, AST, ALT, and hepatitis activities were investigated. The time courses of interface hepatitis relapse in each patient are shown in Figure 5-1, 5-2, and 5-3. AST and ALT levels were strongly correlated with fluorescence intensity. The Pearson's

correlation coefficient (R^2) between the AST level and fluorescence intensity of ARLT for patients 1, 2, and 3 were 0.74, 0.76, and 0.72, respectively. The R^2 between the ALT level and fluorescence intensity of ARLT for patients 1, 2, and 3 were 0.64, 0.99, and 0.80, respectively. The hepatitis activity score was also correlated with fluorescence intensity. Together, these results indicate that ARLT is the cause of liver injury in IPTH.

Immunofluorescence staining during IPTH progression is shown in Figure 5-4. These images represent the time course of IPTH relapse in case 2 (Fig. 5-2), and the four figures in Fig. 5-4 correspond to the four time points in case 2.

Evaluation of the presence of autoantibodies

Next, clinical autoantibodies, which included ANA, LKM, and ASMA, were investigated. The relationship between ARLT and the clinical autoantibodies is shown in Table 6. Seven patients showed ANA positivity, six patients had a titer of 1:40, and one patient had a titer of 1:80. Three patients showed LKM positivity; all were classified as suspicious, not definite. None of the patients was ASMA positive. ARLT presence did not result in a significant

difference in clinical autoantibody levels between the positive and negative groups. This indicates that the presence of ARLT is independent of the presence of clinical autoantibodies.

C4d immunostaining

None of the patients in the IPTH group showed diffuse endothelial C4d staining. The ratio of focal endothelial C4d-positive staining was 50.0% (2/4) in the negative ARLT group, 12.5% (2/16) in the positive ARLT group, and 30.0% (3/10) in the strongly positive ARLT group. There was no significant difference in C4d positivity among the three groups ($p = 0.28$).

DISCUSSION

The complications caused by immunological responses after LTx differ between the early and late phases ^{2,25}. In the early phase, the primary complication is acute cellular rejection caused by HLA mismatch, and thus, inactivation of T lymphocytes by immunosuppressants is crucial to control acute cellular rejection ²⁶⁻²⁸. The development of immunosuppressive drugs has enabled us to overcome this complication ²⁹. The most recent 5-year survival

rate of pediatric LTx recipients is >90%³⁰.

The etiology of late phase complications has not yet been determined; however, recent studies have suggested that antibody-mediated reaction is one of the causes of late phase complications^{6,31-33}. We hypothesized that an antibody-mediated response against liver tissue causes late graft dysfunction, and therefore, we conducted an immunofluorescence analysis with rat liver tissue in the present study. As for the detection of ARLT, it was suspected that the fluorescence intensity was affected by serum IgG level. However, the IPTH group showed higher fluorescence intensity than the control group, without a significant elevation of serum IgG level. Among the patients with IPTH, both the positive and strongly positive groups showed no significant elevation of serum IgG titer, indicating that this immunofluorescence staining was not affected by serum IgG titer and detects only ARLT.

In the subanalysis of the IPTH patients, the ALT level was significantly elevated in the strongly positive group compared with the negative group. During the period when three patients experienced a relapse of IPTH, the AST and ALT levels, and the intensity of immunofluorescence staining, demonstrated a strong correlation in each patient. These results imply that the degree of liver injury is

proportional to the ARLT titer.

Much attention has been paid to HLA-DSA as a cause of antibody-mediated rejection and late graft dysfunction ^{20,24,34-36}. Posttransplantation HLA-DSA has been observed in >40% of all pediatric patients who received LTx, and has a deep correlation with graft liver progressive fibrosis ²⁰. Weaning of calcineurin inhibitors is a risk factor of HLA-DSA ³⁷⁻³⁹. In the present study, the IPTH group showed higher tacrolimus trough level and lower HLA-DSA presence than the control group, consistent with the findings of previous reports. The lower incidence of HLA-DSA in the IPTH group indicated that HLA-DSA has negligible impact on the etiology of IPTH.

The primary immunological difference between HLA-DSA and ARLT is the antigen site and manner of activation. The targets of HLA-DSA are class II HLA, which are expressed in the central vein endothelium and not in the portal tract or hepatocytes ⁴⁰. Furthermore, the central vein endothelia function as antigen-presenting cells ⁴¹. We hypothesize that central vein endothelia present the donor HLA as allo-antigens. T cells then recognize the antigen and activate B cells, which produces HLA-DSA. HLA-DSA presence is treated by increasing the

calcineurin inhibitor dosage. In contrast, the antigens of ARLT exist in the cytoplasm of hepatocytes, according to our study. Antigen-presenting cells must raise an immunological reaction against the ARLT antigen, which may partially explain why the treatment for IPTH requires steroid or metabolic antagonist administration.

Progressive centrilobular-fibrosis has been observed in HLA-DSA-positive patients, whereas fibrosis around the portal tract has been observed in IPTH patients ^{11,20}. In this study, the control group showed higher HLA-DSA positivity, and the fibrosis score of the centrilobular area was significantly higher than that of the portal area. Conversely, the IPTH group showed a higher rate of ARLT, and the fibrosis score of the portal area was significantly higher than that of the centrilobular area.

HLA-DSA against HLA class II are present in >90% of HLA-DSA-positive patients. In the liver tissue, HLA class II antigens are expressed in the central vein endothelium ⁴⁰ and HLA-DSA react mainly with the central vein endothelium, ultimately leading to centrilobular-fibrosis. In IPTH, the limiting plate, which is the location of hepatocytes at the junction of the portal tract and hepatic parenchyma, is the initial target of ARLT, because ARLT react with hepatocytes. Consequently,

IPTH patients show interface hepatitis and fibrosis in the portal area. HLA-DSA are not correlated with IPTH because class II antigens are not expressed in hepatocytes.

C4d is a complement 4 split product that has been used as a marker of antibody-mediated rejection in liver allografts ^{42,43}. In the C4d staining of liver tissue, staining of the vascular endothelium is evaluated, while staining of hepatocytes is considered non-specific. As for HLA-DSA, C4d staining is correlated with HLA-DSA presence ²⁰. However, to our knowledge, C4d staining in IPTH patients has not been reported previously. In our study, C4d staining had no correlation with IPTH or ARLT. HLA-DSA recognize the antigens expressed on the vascular endothelium, and C4d staining is positive when the HLA-DSA and antigen reaction occurs on the vascular endothelium. Our immunofluorescence staining findings suggest that the antigens of ARLT existed in the cytoplasm of hepatocytes. The antigen-antibody reactions would thus occur in the hepatocytes, not in the endothelium. This may explain why C4d and ARLT were not correlated in this histopathological study.

With regard to the etiology of IPTH, it remains unclear whether an autoimmune disorder or rejection against allo-antigens is involved. The

presence of autoantibodies, which would suggest an autoimmune disorder, was previously detected in patients with IPTH ^{1,8,44-46}. Additionally, the presence of anti-cytokeratin (CK) 8/18 antibody was previously detected in AIH patients ⁴⁷. Conversely, it has also been reported that the cause of IPTH is a humoral rejection against an alloantigen ^{10,48,49}.

The mechanism of *de novo* ARLT production remains unknown. In a study of AIH, presumed environmental agents were found to include viruses, drugs, or immunization agents ^{50,51}. Recipients with episodes of acute cellular rejection have been reported to be at a greater risk of IPTH ¹¹. We hypothesize that acute cellular rejection leads to the disruption of hepatocytes; intracellular antigens present in hepatocytes that are normally absent in the peripheral blood are then drained into the bloodstream, where they are exposed to the immune system, resulting in the production of ARLT.

A long interval after LTx is reported to be a risk factor for autoantibody production ⁴⁴. In our study, although the period after LTx in the control group patients matched that in the IPTH patients, ARLT was detected at a significantly higher rate in the IPTH group. Within the IPTH group, there were no significant differences in the interval between LTx and the onset of IPTH, or in the follow-up

period after LTx. These findings indicate that ARLT is only marginally correlated with the period after LTx.

There are some limitations associated with the present study. Firstly, the specific ARLT were not identified. Secondly, the immunofluorescence staining analysis showed similar hepatocyte staining patterns; however, it is possible that different antibodies show the same staining pattern, and all the patients who showed positive or strongly positive staining may not have the same ARLT. Further studies using SDS-PAGE are currently underway to clarify the precise role of the antibodies in IPTH.

In conclusion, the etiology of IPTH is antibody-mediated, and ARLT, not HLA-DSA, are correlated with IPTH and reflect the activity of IPTH. The pathogenic immunogenicity in patients with IPTH does not decline because the allo-antigens present in the graft liver never disappear. This may explain why therapy for patients with IPTH consists of steroid and/or antimetabolites (e.g., mycophenolate mofetil and mizoribine) and why a dose reduction of these immunosuppressants is difficult in patients with IPTH.

Acknowledgments

We thank Dr. Takeshi Watanabe (Center for Innovation in Immunoregulative Technology and Therapeutics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan) for helpful discussions regarding the evaluation of immunofluorescence staining.

References

1. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. *Hepatology*. 2006;43(5):1109-1117.
2. Banff Working G, Demetris AJ, Adeyi O, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. *Hepatology*. 2006;44(2):489-501.
3. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2008;14(6):861-871.
4. Desai M, Neuberger J. Chronic liver allograft dysfunction. *Transplantation proceedings*. 2009;41(2):773-776.
5. Scheenstra R, Peeters PM, Verkade HJ, Gouw AS. Graft fibrosis after pediatric liver transplantation: ten years of follow-up. *Hepatology*. 2009;49(3):880-886.
6. Egawa H, Miyagawa-Hayashino A, Haga H, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. *Hepatology research : the official journal of the Japan Society of Hepatology*. 2012;42(9):895-903.
7. Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Uemoto S, Manabe T. Idiopathic post-transplantation hepatitis following living donor liver transplantation, and significance of autoantibody titre for outcome. *Transplant International*. 2009;22(3):303-312.
8. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. *The Lancet*. 1998;351(9100):409-413.
9. Hernandez HM, Kovarik P, Whittington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. *Journal of pediatric gastroenterology and nutrition*. 2001;32(2):131-136.
10. Miyagawa-Hayashino A, Haga H, Sakurai T, Shirase T, Manabe T, Egawa H. De novo autoimmune hepatitis affecting allograft but not the native liver in

- auxiliary partial orthotopic liver transplantation. *Transplantation*. 2003;76(1):271-272.
11. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and Risk Factors of De Novo Autoimmune Hepatitis in Living-Donor Liver Transplantation. *Transplantation*. 2004;78(1):128-135.
 12. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2007;7(4):955-963.
 13. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. *Transplantation*. 2001;72(2):267-272.
 14. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. *Transplantation*. 1996;61(2):247-252.
 15. Ueda M, Oike F, Ogura Y, et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2006;12(9):1326-1336.
 16. Kasahara M, Kiuchi T, Takakura K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection. *Transplantation*. 1999;67(4):568-575.
 17. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. *Hepatology*. 1994;20(1 Pt 1):15-20.
 18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology*. 1996;24(2):289-293.
 19. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *Journal of hepatology*. 2007;47(4):598-607.
 20. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2012;18(11):1333-1342.

21. Kern P, Kron M, Hiesche K. Measurement of antinuclear antibodies: assessment of different test systems. *Clinical and diagnostic laboratory immunology*. 2000;7(1):72-78.
22. Prost AC, Abuaf N, Rouquette-Gally AM, Homberg JC, Combrisson A. Comparing HEp-2 cell line with rat liver in routine screening test for antinuclear and antinucleolar autoantibodies in autoimmune diseases. *Annales de biologie clinique*. 1987;45(6):610-617.
23. Casavant CH, Hart AC, Stites DP. Comparison of a semiautomated fluorescent immunoassay system and indirect immunofluorescence for detection of antinuclear antibodies in human serum. *Journal of clinical microbiology*. 1979;10(5):712-718.
24. Yoshizawa A, Egawa H, Yurugi K, et al. Significance of semiquantitative assessment of preformed donor-specific antibody using luminex single bead assay in living related liver transplantation. *Clinical & developmental immunology*. 2013;2013:972705.
25. Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. *Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 1999;5(4):261-268.
26. Millan O, Rafael-Valdivia L, Torrademe E, et al. Intracellular IFN-gamma and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. *Cytokine*. 2013;61(2):556-564.
27. Rodriguez-Peralvarez M, Rico-Juri JM, Tsochatzis E, Burra P, De la Mata M, Lerut J. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. *Transplant international : official journal of the European Society for Organ Transplantation*. 2016;29(9):961-973.
28. Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. *Hum Immunol*. 2013;74(11):1478-1485.
29. Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. *World J Gastroenterol*. 2009;15(34):4225-4233.
30. Kasahara M, Umeshita K, Inomata Y, Uemoto S. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more

- than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2013;13(7):1830-1839.
31. Markiewicz-Kijewska M, Kalicinski P, Kluge P, et al. Antibody-mediated rejection in pediatric liver transplant recipients. *Ann Transplant*. 2014;19:119-123.
 32. Taner T, Stegall MD, Heimbach JK. Antibody-mediated rejection in liver transplantation: current controversies and future directions. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2014;20(5):514-527.
 33. Martelius T, Halme L, Arola J, Hockerstedt K, Lautenschlager I. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. *Transplant immunology*. 2009;21(4):244-246.
 34. Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. *Transplantation*. 2015;99(7):1416-1422.
 35. Grabhorn E, Binder TM, Obrecht D, et al. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation. *Transplantation*. 2015;99(9):1876-1881.
 36. Cuadrado A, San Segundo D, Lopez-Hoyos M, Crespo J, Fabrega E. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. *World J Gastroenterol*. 2015;21(39):11016-11026.
 37. Perbos E, Juinier E, Guidicelli G, et al. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. *Clinical transplantation*. 2014;28(9):1054-1060.
 38. O'Leary JG, Samaniego M, Barrio MC, et al. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. *Transplantation*. 2016;100(1):39-53.
 39. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. *American journal of transplantation : official journal of the American Society*

- of Transplantation and the American Society of Transplant Surgeons.* 2013;13(6):1541-1548.
40. Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. *Journal of clinical pathology.* 1987;40(8):879-884.
 41. Rose ML. Endothelial cells as antigen-presenting cells: role in human transplant rejection. *Cellular and molecular life sciences : CMLS.* 1998;54(9):965-978.
 42. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.* 2007;20(6):676-684.
 43. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.* 2006;12(3):457-464.
 44. Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. *Journal of pediatric gastroenterology and nutrition.* 2007;45(2):222-227.
 45. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. *Journal of hepatology.* 2004;40(1):3-7.
 46. Demetris AJ, Sebach M. Plasma cell hepatitis in liver allografts: Variant of rejection or autoimmune hepatitis? *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.* 2008;14(6):750-755.
 47. Inui A, Sogo T, Komatsu H, Miyakawa H, Fujisawa T. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.* 2005;11(5):504-507.
 48. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. *Hepatology.* 2002;35(2):349-356.

49. Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2009;15(5):530-539.
50. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. *Lancet*. 1991;337(8751):1183-1187.
51. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. *Hepatology*. 1994;19(3):609-615.

Table 1 Patient Characteristics

	IPTH	Control	<i>p</i> Value
	(n=30)	(n=42)	
Patient age at LTx	6.4 (0.2 - 18.7)	4.5 (0.9 - 19.3)	0.10
Follow-up period	11.9 (1.3 - 21.5)	9.7 (1.0 - 19.5)	0.11
Gender			
Male	8	18	0.19
Female	22	24	
Original disease			
Biliary atresia	26	33	0.37
Alagille syndrome	0	2	
Fulminant hepatitis	0	2	
Hepatoblastoma	0	3	
PFIC	1	1	
Metabolic disease	3	0	
Neonatal hepatitis	0	1	
Graft type			
Monosegment	1	0	0.50

Lateral segment	22	35	
Left lobe	6	6	
Right lobe	1	2	
Current immunosuppression			
No immunosuppression	0	3	<0.001
CNI	3	27	
CNI+MMF	1	2	
CNI+steroid	11	4	
CNI+MMF+steroid	15	6	

LTx, liver transplantation; PFIC, progressive familial intrahepatic cholestasis

CNI: calcineurin inhibitor, MMF: mycophenolate mefetil

Table 2 Result of ARLT and HLA-DSA

		IPTH (n=30)	Control (n=42)	<i>p</i> Value
		n (%)	n (%)	
ARLT	Positive	26 (86.7)	13 (30.9)	<0.001
	Negative	4 (13.3)	29 (69.1)	
HLA-DSA	Positive	3 (12.5)	19 (50.0)	0.0011
	Class I	0 (0)	3 (7.9)	
	Class II	3 (10.0)	18 (47.3)	
	DQ	2 (6.6)	14 (36.8)	
	DR	2 (6.6)	15 (39.5)	
	Negative	21 (87.5)	19 (50.0)	

ARLT, antibodies reacting liver tissue; HLA-DSA, donor-specific anti-human leukocyte antigens antibodies

Table 3 Clinical Data of 4 Pathological Groups

	Control				<i>p</i> Value
	IPTH	Inflammation	Fibrosis	Normal	
	(n=30)	(n=13)	(n=14)	(n=15)	
AST (IU/L)	55.7±115.3	63.1±46.8	42.6±36.2	24.9±9.8	0.56
ALT (IU/L)	49.2±84.0	66.7±61.2	34.6±34.1	37.9±61.4	0.61
g-GTP (IU/L)	118.8±173.0	87.6±176.2	23.6±11.5	47.1±103.1	0.22
T-Bil (md/dL)	0.9±0.8	1.1±1.3	0.9±0.6	1.2±1.3	0.74
Plt (x10 ⁴ /ml)	17.1±9.1	15.0±4.9	15.3±5.7	17.7±7.7	0.70
IgG (mg/dL)	1524±864	1003±387	1325±413	1249±293	0.16
Tacrolimus trough level (ng/ml)	4.4±1.8	3.5±2.2	2.1±1.6	3.9±3.0	0.04

IPTH, idiopathic post-transplantation hepatitis; LTx, liver transplantation

Table 4 Location of Severe Fibrosis

	Control				<i>p</i> Value
	IPTH	Inflammation	Fibrosis	Normal	
	(n=30)	(n=13)	(n=14)	(n=15)	
	n (%)	n (%)	n (%)	n (%)	
Portal area	18 (60.0)	3 (23.1)	6 (42.8)	1 (6.6)	0.002
Centrilobular area	6 (20.0)	2 (15.3)	12 (85.7)	2 (13.3)	<0.001

Table 5 Clinical Data of IPTH Patients Classified with ARLT

	ARLT			<i>p</i> Value
	Negative	Postive	Strongly Positive	
	(n=4)	(n=16)	(n=10)	
Age at LTx (years)	9.1±5.9	9.9±8.7	9.6±8.9	0.98
Follow-up period (years)	12.1±8.1	11.8±6.3	12.8±1.7	0.91
IPTH onset from LTx (years)	6.5±9.4	6.7±7.8	7.8±5.7	0.87
AST (IU/L)	24.5±5.6	27.8±13.3	56.7±61.6	0.12
ALT (IU/L)	22.3±15.8	23.7±14.4	56.3±51.3	0.035
g-GTP (IU/L)	97.3±94.9	79.7±112.3	163.8±234.8	0.41
T-Bil (md/dL)	0.8±0.2	0.8±0.3	0.9±0.5	0.57
IgG (mg/dL)	941±230	1640±1049	1508±464	0.43

ARLT, antibodies that react with liver tissue; IPTH, idiopathic post-transplantation hepatitis; LTx, liver transplantation;

Table 6 Relation of Clinical Autoantibodies and ARLT

		Clinical autoantibodies		<i>p Value</i>
		Negative (n=20)	Positive (n=10)	
		n (%)	n (%)	
ARLT	Negative	3 (15.0)	1 (10.0)	0.72
	Positive	10 (50.0)	6 (60.0)	
	Strongly positive	7 (35.0)	3(30.0)	

ARLT, antibodies that react with liver tissue;

Figure Legends

Figure 1. Patient classification.

Thirty idiopathic posttransplantation hepatitis (IPTH) patients and 42 control patients with matching background, including age at liver transplantation (LTx), follow-up period, and gender, were enrolled. The control group was classified into three subgroups according to the pathological findings (inflammation, fibrosis, and normal).

In a subanalysis of the IPTH patients, the IPTH group was classified into three subgroups according to the immunofluorescence staining results (negative, positive, and strongly positive).

Figure 2. Immunofluorescence staining patterns.

(1) Strongly positive, (2) positive, (3) negative, and (4) negative control (healthy volunteer).

Each patient's serum served as the primary antibody, while anti-human IgG antibody conjugated to CF488A Dye served as the secondary antibody. There was no cross-reactivity of the secondary antibody to rat liver tissue. All images were obtained at 100× magnification.

Staining of the hepatocyte cytoplasm was evaluated. Kupffer cells and the vascular endothelium showed higher staining intensity than hepatocytes, even with the serum of the healthy volunteer, and intense staining of Kupffer cells or the vascular endothelium was considered non-specific.

Figure 3. Fluorescence intensity of antibodies that react with liver tissue (ARLT) and donor-specific anti-human leucocyte antigens (HLA-DSA).

3-1 Fluorescence intensity of ARLT in the four groups classified according to the pathological findings.

Patients with IPTH showed higher fluorescence intensity than other patients, and a significant difference was noted between patients with IPTH and the other groups. $*p < 0.001$.

3-2 Mean fluorescence intensity (MFI) of HLA-DSA.

The IPTH group showed a significantly lower MFI than the other groups. $**p = 0.001$

Figure 4: IgG subclass immunofluorescence staining of IPTH patients.

4-1 IgG1, 4-2 IgG2, 4-3 IgG3, 4-4 IgG4. Twenty-four of 26 ARLT-positive patients

were IgG1-positive.

Figure 5: Time course of the IPTH relapse patients.

Fig. 5-1, 5-2, and 5-3 shows the time course of the pathological findings, AST level, ALT level, and the fluorescence intensity of ARLT. Three patients experienced relapse and remission of IPTH. The fluorescence intensity of ARLT was correlated with the AST level, ALT level, and pathological findings. The R^2 between AST and ARLT and between ALT and ARLT for patient 1, 2, and 3 were 0.74, 0.76, and 0.72 and 0.64, 0.99, and 0.80 respectively.

The X-axis represents months after LTx. The left Y-axis shows the levels of AST and ALT, and the right Y-axis shows the intensity of immunofluorescence staining. A1 and A2 illustrate the hepatitis activity score according to the METAVIR scoring system.

Fig. 5-4 shows the immunofluorescence staining during IPTH progression in a patient. The four figures (a), (b), (c), and (d) correspond to the time points (a), (b), (c), and (d), respectively, in Fig. 5-2.

Figure 1

ARLT and HLA-DSA analysis




Figure 2-1




Figure 2-2




Figure 2-3




Figure 2-4




Figure 3

Figure 3-1




Figure 3-2




Figure 4-1




Figure 4-2



Figure 4-3




Figure 4-4




Figure 5-1




Figure 5-2




Figure 5-3




Fig 5-4

